Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors

Inclusion Criteria

• •Male or female participants ≥18 years of age at the time of signing the informed consent
• •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• •Participant must have one of the following that has progressed or was non-responsive to prior systemic therapy and for which no standard or available known therapeutic option exists:
• •1. locally advanced or metastatic epithelial ovarian cancer (including fallopian tube or primary peritoneal), or
• •2. metastatic breast cancer, or
• •3. metastatic castration-resistant prostate cancer (mCRPC), or
• •4. pancreatic adenocarcinoma
• •Measurable disease per RECIST v1.1 (exceptions for participants with non-measurable but evaluable disease \[per RECIST and or PSA/CA-125\])
• •Next generation sequencing (NGS) report demonstrating eligible tumor biomarker
• •Provision of archival tumor tissue, or if adequate archival tumor tissue is not available, provision of a fresh biopsy if there is a lesion that can be safely biopsied
• •Acceptable organ function at Screening
• •Acceptable hematologic function at Screening
• •Life expectancy ≥12 weeks after the start of the treatment according to the Investigator's judgment